OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Monitoring and Managing Lorlatinib Adverse Events in the Portuguese Clinical Setting: A Position Paper
Fernando Barata, Carlos Aguíar, Tiago Reis Marques, et al.
Drug Safety (2021) Vol. 44, Iss. 8, pp. 825-834
Closed Access | Times Cited: 8
Fernando Barata, Carlos Aguíar, Tiago Reis Marques, et al.
Drug Safety (2021) Vol. 44, Iss. 8, pp. 825-834
Closed Access | Times Cited: 8
Showing 8 citing articles:
A pragmatic guide for management of adverse events associated with lorlatinib
Geoffrey Liu, Julien Mazières, Jan A. Stratmann, et al.
Lung Cancer (2024) Vol. 191, pp. 107535-107535
Open Access | Times Cited: 13
Geoffrey Liu, Julien Mazières, Jan A. Stratmann, et al.
Lung Cancer (2024) Vol. 191, pp. 107535-107535
Open Access | Times Cited: 13
Psychiatric Adverse Reactions to Anaplastic Lymphoma Kinase Inhibitors in Non-Small-Cell Lung Cancer: Analysis of Spontaneous Reports Submitted to the FDA Adverse Event Reporting System
Monia Sisi, Michele Fusaroli, Andrea De Giglio, et al.
Targeted Oncology (2022) Vol. 17, Iss. 1, pp. 43-51
Open Access | Times Cited: 20
Monia Sisi, Michele Fusaroli, Andrea De Giglio, et al.
Targeted Oncology (2022) Vol. 17, Iss. 1, pp. 43-51
Open Access | Times Cited: 20
Expert Consensus on the Management of Adverse Events of Lorlatinib in the Treatment of ALK+ Advanced Non-small Cell Lung Cancer
Edurne Arriola, Javier de Castro, Rosario García-Campelo, et al.
Clinical Drug Investigation (2024) Vol. 44, Iss. 8, pp. 553-576
Open Access | Times Cited: 2
Edurne Arriola, Javier de Castro, Rosario García-Campelo, et al.
Clinical Drug Investigation (2024) Vol. 44, Iss. 8, pp. 553-576
Open Access | Times Cited: 2
New findings on the incidence and management of CNS adverse reactions in ALK-positive NSCLC with lorlatinib treatment
F L Chu, Wenxi Zhang, Hong Hu
Discover Oncology (2024) Vol. 15, Iss. 1
Open Access | Times Cited: 2
F L Chu, Wenxi Zhang, Hong Hu
Discover Oncology (2024) Vol. 15, Iss. 1
Open Access | Times Cited: 2
Lorlatinib as a treatment for ALK-positive lung cancer
Keisuke Baba, Yasushi Goto
Future Oncology (2022) Vol. 18, Iss. 24, pp. 2745-2766
Open Access | Times Cited: 11
Keisuke Baba, Yasushi Goto
Future Oncology (2022) Vol. 18, Iss. 24, pp. 2745-2766
Open Access | Times Cited: 11
Safety of Lorlatinib in ALK-Positive Non-Small-Cell Lung Cancer and Management of Central Nervous System Adverse Events
Saadettin Kılıçkap, Sertaç Ak, Oldac Uras Dursun, et al.
Future Oncology (2023) Vol. 19, Iss. 29, pp. 2003-2012
Open Access | Times Cited: 6
Saadettin Kılıçkap, Sertaç Ak, Oldac Uras Dursun, et al.
Future Oncology (2023) Vol. 19, Iss. 29, pp. 2003-2012
Open Access | Times Cited: 6
Diagnosis and Treatment of Advanced ALK Rearrangement-Positive Non-Small-Cell Lung Cancer in Portugal: Results of a National Questionnaire
Ana Figueiredo, Ana Rodrigues, Carina Gaspar, et al.
Drugs - Real World Outcomes (2023) Vol. 10, Iss. 4, pp. 545-555
Open Access | Times Cited: 1
Ana Figueiredo, Ana Rodrigues, Carina Gaspar, et al.
Drugs - Real World Outcomes (2023) Vol. 10, Iss. 4, pp. 545-555
Open Access | Times Cited: 1
[Chinese Expert Consensus on Management of Special Adverse Effects
Associated with Lorlatinib].
Qing Zhou, Shun Lü, Yong Li, et al.
DOAJ (DOAJ: Directory of Open Access Journals) (2022) Vol. 25, Iss. 8, pp. 555-566
Closed Access | Times Cited: 2
Qing Zhou, Shun Lü, Yong Li, et al.
DOAJ (DOAJ: Directory of Open Access Journals) (2022) Vol. 25, Iss. 8, pp. 555-566
Closed Access | Times Cited: 2
